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Abstract: Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has
been largely underestimated, and the disease was considered a T-cell-mediated disorder. However,
newer evidence shows that B cells play a crucial role in the pathogenesis of MS via antigen-driven
autoantibody responses and through the cross regulation of T-helper cells. As B cells express the
surface molecule CD20 at all points of differentiation, it provides a specific target for monoclonal
antibodies, and the development and clinical testing of anti-CD20 antibody treatments for MS have
been successful. After some observations, some small clinical trials found positive effects for the first
anti-CD20 therapeutic rituximab in MS; newer agents have been specifically evaluated, resulting in
the development of ocrelizumab and ofatumumab. Ocrelizumab, a humanized anti-CD20 monoclonal
antibody, was approved in March 2017 by the Food and Drug Administration (FDA) and is also the
first proven therapy to reduce disability progression in primary progressive MS. This is particularly
significant considering that disease-modifying treatment options are few for both primary and
secondary progressive MS. Ofatumumab, a fully human anti-CD20 monoclonal antibody, that binds
a distinct epitope, has been further investigated in phase 3 trials for relapsing forms of MS. In this
review, we discuss in detail these two anti-CD20 agents and their advent for treatment of MS.
Keywords: monoclonal antibodies; multiple sclerosis; B-cell therapies; safety
1. Introduction
Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous
system (CNS) characterized by the accumulation of inflammatory cells and cytokines at the sites
of demyelination and plaque formation [1]. MS is known for its chronic degenerative effect on the
neurological system leading to diverse progression patterns, giving rise to a number of phenotypes.
MS is broadly categorized into three major subtypes: relapsing–remitting MS (RRMS), progressive
MS, and clinically isolated syndromes (CIS) [2]. RRMS is characterized by episodes of disease activity,
with new or expanding CNS lesions, while progressive disease is characterized by a gradual worsening
of clinical symptoms over time which may or may not be accompanied by inflammatory activity.
The majority of those diagnosed with MS have RRMS (85%) which, over time in some patients,
progresses to secondary progressive MS (SPMS), in which worsening disease leads to progression of
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clinical symptoms. A section of patients (10–15%) are diagnosed with primary progressive MS (PPMS);
this subgroup is treated as a distinct type of MS, characterized by ongoing clinical deterioration [2].
The symptoms of MS and the progression of the disease vary, with some individuals having very few
symptoms whilst others require a range of assistive therapies and mobility aids for function such
as walkers or wheelchairs [3]. Important clinical measures for MS include the Expanded Disability
Status Score (EDSS), which is a measure of a broad range of impairments including tremor, weakness,
incontinence, and speech difficulties, among others; the relapse rate, which measures the speed of
new neurological symptom onset over time; and magnetic resonance imaging (MRI) findings, such as
gadolinium-enhancing lesions which indicate inflammation of a plaque, or T2 lesions which indicate
broader MS plaque volume. These measures are critical to clinical decision making, particularly in the
realm of drug prescription and treatment. The progression of disability, inflammatory disease activity,
clinical relapse, and radiographical changes in the CNS are all indicators for particular therapeutic
interventions, and should guide decision making. The ultimate goal of modern MS therapies is to
achieve no evidence of disease activity (NEDA) in which therapy has halted relapses and disability
progression, as well as new and active MRI lesion development. There are a number of drugs available
for MS patients; however, while they decrease the relapse rate of RRMS, safety concerns, individual
immunological changes, and issues with compliance make their long-term use challenging. Effective
treatments for the progressive forms of MS are more limited, with only a small number of therapeutic
agents available with beneficial effects. Hence, there is a requirement for new improved treatment
modalities to effectively treat MS [4–6].
2. T- and B-Cell Hypothesis
MS is characterized as a complex inflammatory disease, where T helper (Th) 1, Th2, Th9, Th17,
Th22 cells, CD4+, CD8+ T cells, B cells, and M1 macrophages infiltrate the sites of neuronal, blood–brain
barrier, myelin damage, and glial activation [4]. This immune response results in cytokine secretion
(Interleukin [IL] -2, IL-6, IL-9, IL-12, IL-17, IL-22, IL-23, IL-27, interferon [IFN]-gamma, tumor necrosis
factor [TNF]-alpha) and activation of an inflammatory storm leading to axonal damage, gliosis,
disruption of the blood–brain barrier, and demyelination within the brain and spinal cord [7–9].
Thus, it is appropriate to target specific immune cells and/or their constituents rather than global
immunosuppression to reduce side effects and modulate inflammation. Historically, MS was seen
as a T-cell pathology; however, it is now known that B cells play a large role in the pathogenesis of
the disease. Dysfunctional regulation of B cells and Th cells leads to ongoing autoimmune activation
against the myelin sheath. Lymphocytes can cross the blood–brain barrier, through a complex process
of extravasation, and enter the brain parenchyma. Initially it is thought that an autoimmune trigger
causes Th-cell trafficking to the CNS, which in turn activates and attracts B cells to the affected area.
These B cells acquire self-antigens, differentiate to antibody-producing plasma cells, and begin the
production of auto-antibodies against neural tissues. B cells also co-regulate the Th cells, leading to
further immune cell trafficking to the region of dysfunction. A majority of MS patients are known to
have accumulation of both immune cells, auto-antibodies, cytokines, and inflammatory mediators in
the cerebrospinal fluid, particularly during times of relapse or increased disease activity, clear evidence
of an accelerated inflammatory immune response underpinning its pathogenesis. The immune cells
which have migrated to the CNS aggregate in an organized tertiary ectopic follicle, which are known
to remain active; however, their contribution to the ongoing disease is not yet fully understood [10].
While the role of B cells in the pathogenesis of MS is clear, there are still many unanswered questions.
The factors which are involved in their trafficking to the CNS, the exact mechanisms by which they
cross the blood–brain barrier, as well as their behavior after the cessation of the inflammatory period
are yet to be fully understood. Despite these unknowns, the success of B-cell depleting therapies [11]
has reinforced the modern understanding of the pathophysiological perception of MS, as a disease of
both T and B cells [12,13].
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B cells are classified as regulatory B cells (which secrete IL-10, IL-35) and, importantly in MS,
as pro-inflammatory B cells (which secrete IL-6, IL-12, IL-15, TNF-alpha, granulocyte macrophage colony
stimulating factor [GM-CSF]) that regulate T-cell polarization towards pro-inflammatory immune
responses (Figure 1) [12,14]. In addition, B cells, alongside other antigen-presenting cells, play a highly
effective role in antigen processing and presentation as they express the major histocompatibility
complex and T-cell activation surface markers CD80, CD86 leading to further activation of T cells in
MS (Figure 1) [15,16]. Furthermore, in MS, B cells are clonally expanded and secrete autoantibodies
(IgG) with oligoclonal bands noted in the cerebrospinal fluid and brain parenchyma in most (>90%)
patients [17]. Antigen-specific memory B cells are also present in the central nervous system of patients
with MS, and are detected in MS lesions [18,19]. Clearly, B cells are present within the central nervous
system in individuals living with MS, suggesting that they play a major part in the pathophysiology
and course of disease. Depletion of B cells has been shown to be a viable approach as a therapeutic
target against MS.
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highly expressed on the surface of B cells, and plays a role in their differentiation into plasma cells
and activation of antigen independent T-cell responses. CD20 is expressed by B-cell lymphomas and
leukemias and some myelomas, thymomas and Hodgkin’s disease [21,22]. While classically CD20
was thought to be exclusively a B-cell marker, it has also been identified on a small subset of T cells;
however, it is unclear whether their depletion is responsible for some of the effects of anti-CD20
therapies [23]. Using antibody therapies to deplete B cells allows the pathogenic cycle of inflammation
and immune-mediated CNS injury to be broken and allow for longer periods between relapses. This
comes alongside a host of clinical benefits, with a decreased and slowed progression of disability. There
is growing research interest surrounding the use of anti-CD20 antibodies as a treatment for all forms
of MS [24,25]. Targeting CD20 using monoclonal antibodies has shown to be revolutionary against
B-cell leukemias and lymphomas and more recently against autoimmune diseases where B cells play a
fundamental role, such as systemic lupus erythematosus and MS [26,27].
3. Anti-CD20 Agents
A number of anti-CD20 monoclonal antibodies have been approved and used in human clinical
trials, primarily, obinutuzumab, tositumomab, ublituximab, ocrelizumab, ofatumumab and rituximab.
Briefly, obinutuzumab (also known as afutuzumab, GA101; by GlycArt Biotechnology AG and Roche)
is a humanized monoclonal antibody (from mouse) used intravenously against chronic lymphocytic
leukemia, non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, and was approved by the
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2013 under
the trade names Gazyva and Gazyvaro, respectively [28]. Tositumomab (also known as Bexxar;
by GlaxoSmithKline) is an 131-Iodine-labeled murine monoclonal antibody that was approved for
use in non-Hodgkin’s lymphoma in 2003 [29]. The radiolabeled antibody was used to increase the
radiation delivered to the tumor with less overall body radiation exposure; however, in 2014, Bexxar
was discontinued due to lack of demand as newer, improved anti-CD20 antibodies were available.
Ublituximab (TG-1101; by TG Therapeutics) is a chimeric glycol-mouse/human anti-CD20 monoclonal
antibody currently in phase II human clinical trial for chronic lymphocytic leukemia. In addition,
a phase III randomized, multicenter, double-blind clinical trial is being compared against teriflunomide,
and is currently recruiting patients with RRMS with an estimated completion date of 30 September
2021 (registration no. NCT03277261). In MS more broadly, there are three major anti-CD20 therapies
available, Rituximab, Ocrelizumab, and Ofatumumab [30].
The first anti-CD20 therapy to be used in MS is the chimeric antibody Rituximab. Rituximab
(also known as Rituxan or MabThera; by Biogen and Genentech, USA and Hoffmann-La Roche,
Canada) was approved in 1997 for some cancers and for autoimmune disorders and is on the WHO’s
list of essential medicines [31]. While rituximab is not FDA- or EMA-approved for use in MS, it is
commonly prescribed off-label, particularly in resistant cases. Rituximab biosimilar compounds are
currently under investigation, with a number currently under investigation [32]. Despite its common
use in MS, there are relatively few high-quality studies surrounding its efficacy. In the first phase I
clinical trial of rituximab, named HERMES, 69 patients with RRMS were given 1000 mg of rituximab,
and compared against placebo-treated controls [33]. The patients receiving rituximab had reduced total,
and new gadolinium-enhancing lesions at 12, 16, 20, and 24 weeks compared to controls (p = < 0.001).
The patients receiving the treatment also had fewer relapses than controls at both 24 and 48 weeks
(14.5% vs. 34.3%, p = 0.02) and a decrease in the annualized relapse rate (ARR) at 24 weeks (0.37
vs. 0.84, p = 0.04), but not at 48 weeks. The phase I HERMES trial was followed up by a phase
2/3 trial of 439 patients with PPMS named OLYMPUS which evaluated the effect of Rituximab on
disease progression [34]. Note that 292 patients received 1000 mg of rituximab at weeks 0, 2, 24, 26, 48,
50, 72, and 74, and were compared against placebo-treated controls. The trial demonstrated mixed
results, with no difference in time to disease progression, brain volume loss, or a number of functional
criteria of the multiple sclerosis functional composite. There was however a decrease in T2-weighted
lesion volume on MRI, and an improvement in 25-foot walk test. While level 1 evidence is lacking,
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there are a small number of observational and cohort studies which support the use of rituximab in MS.
These studies have shown that the medication appears to improve MRI and clinical findings in RRMS,
PPMS, and SPMS, with reduced ARR, T2, and gadolinium-enhancing lesions [35–39]. The clinical
studies on rituximab are summarized in Table 1. While on balance the evidence suggests that rituximab
is likely to have beneficial effects, particularly in RRMS, in light of the newer agents ocrelizumab and
ofatumumab becoming more broadly available and having stronger therapeutic efficacy, interest in its
use is declining. There are however currently ongoing clinical trials, which may provide new evidence
of positive effect.
Table 1. A Summary of Clinical Studies Using Rituximab.
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MS: Multiple sclerosis, MRI: Magnetic resonance imaging, GAD: Gadolinium, AE: Adverse event, RRMS: Relapsing
remitting MS, PPMS: Primary progressive MS, SPMS: Secondary progressive MS, ARR: Annualize relapse rate,
EDSS: Expanded disability status scale, MSFC: MS functional composite.
4. Ocrelizumab
Ocrelizumab (also known as Ocrevus®; marketed by Genentech, US) is a humanized anti-CD20
monoclonal antibody (from mouse) which binds to an overlapping epitope to that of rituximab and
is used intravenously. Ocrelizumab specifically depletes B cells and was approved by the FDA in
March 2017 for the treatment of MS, in particular those with active PPMS [40,41]. The EMA approval
followed 9 months after the USA approval, and it introduced a new era of B-cell-targeted treatment of
MS. The acceptance of anti-CD20 agents is reflected in the market share of Ocrevus®, which accounted
for an estimated 13.8% of MS medication sales a year after release [42].
4.1. Dosage and Administration
The starting concentration to be used is generally 300 mg in 250 mL 0.9% NaCl (i.e., 1.2 mg/mL),
followed by a second injection after 2 weeks, and thereafter every 6 months of 600 mg in 500 mL 0.9%
NaCl, intravenously. Prior to ocrelizumab injection, patients are required to be premedicated at least
30–60 min prior with 100 mg methylprednisolone (or an equivalent) and an antihistamine, in order to
avoid infusion-related reactions. Patients are required to be observed for at least 60 min following
ocrelizumab infusion [43].
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4.2. Pharmacology and Pharmacokinetics
Ocrelizumab is a humanized anti-CD20 IgG1 mAb which binds to the extracellular loop
of CD20, causing antibody-dependent cell lysis in circulating B cells. The mechanisms of
apoptotic B-cell depletion with ocrelizumab use are antibody-dependent cell-mediated phagocytosis,
antibody-dependent cellular cytotoxicity (ADCC), as well as complement-dependent cytotoxicity
(CDC) [43,44]. Interestingly, recent studies have shown that ocrelizumab may also target CD20+ T cells,
which are shown to be present in MS patients, suggesting an alternative contributing mechanism [23].
Ocrelizumab shows effectively linear, dose-proportional pharmacokinetics for doses of 400 mg to
2000 mg. Ocrelizumab, as with other antibodies, undergoes nonspecific catabolism and degrades into
smaller peptides and amino acids when metabolized, with a half-life of 26 days [41].
4.3. Clinical Trials
The following studies have examined the efficacy and safety of ocrelizumab in RRMS patients,
as shown in Table 2. In a phase 2, 48-week, double-blind, randomized parallel, placebo-controlled trial,
220 patients with RRMS received two doses of either an intravenous placebo, a low dose (600 mg), or a
high dose (2000 mg) of ocrelizumab on days 1 and 15, alongside a control group receiving a weekly
30 µg dose of interferon beta-1a (IFN-beta-1a) [45]. After 24 weeks, there was a significant reduction in
the number of gadolinium-enhancing lesions, with decreases of 89% in the low-dose group and 96%
in the 2000 mg group, with no difference in serum IgG. Infusion-related adverse effects, most often
infections and headache, were reported as more serious in the 2000 mg group compared to patients
receiving the lower dose, but incidence of these side effects was equivalent in both groups (35% in
the 600 mg vs. 44% in the 2000 mg group in cycle 1, and 16% vs. 17% in cycle 2). Only 9% of RRMS
patients tested with IFN-beta-1a experienced infusion-associated adverse effects, and there was one
death reported on trial in the high-dose ocrelizumab group after complications following a bee sting.
Table 2. A Summary of Clinical Trials Using Ocrelizumab.
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MS, Multiple Sclerosis; RRMS, Relapsing Remitting Multiple Sclerosis; wk, week; ARR, Annualized Relapse Rate;
GAD, gadolinium.
Two equivalent phase 3, randomized and double-blind clinical trials named OPERA 1 and 2
were conducted to test the efficacy of ocrelizumab versus IFN-beta-1a in RRMS patients [46]. The two
studies had the same duration (96 weeks) and randomized 821 and 835 RRMS patients, aged 18 to
55 years. The participants received either 600 mg of intravenous ocrelizumab every 24 weeks or 44 µg
of subcutaneous IFN-beta-1a three times weekly. The group given the ocrelizumab received their first
dose as two infusions of 300 mg each, given two weeks apart, with the remaining doses at the 24 week
interval. The trials included patients with an Expanded Disability Status Score (EDSS) between 0 and
5.5 and who had suffered more than two clinical relapses in the two years prior to the study, or at least
one in the past year. Both studies showed a significant decrease in the annualized relapse rate (ARR)
for patients treated with ocrelizumab at 96 weeks than those treated with IFN-beta-1a (0.16 versus
0.29, p = < 0.001). The percentage of patients with progression in their disability was lower at both 12
(9.1 vs. 13.6% p = < 0.001) and 24 weeks (6.9 vs. 10.5% p = 0.003). There was also a 94% decrease in
gadolinium-enhancing lesions with ocrelizumab compared with placebo in both trials. The mean new
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or newly expanding lesions on T2-weighted MRI imaging was significantly lower in the group given
ocrelizumab versus the interferon beta-1a group in both trials.
In a 120 week, double-blind and placebo-controlled phase 3 trial named ORATORIO [47], a total of
732 patients with PPMS were randomized to receive 600 mg of ocrelizumab intravenously or placebo
every 24 weeks at a ratio of 2:1. Participants included were aged 18–55 years with a diagnosis of PPMS
through the McDonald criteria [48], characterized by oligoclonal bands suggestive of elevated IgG in
the CSF and had an EDSS score of 3.0–6.5 at screening [47]. The patients receiving ocrelizumab had
lower disability progression at week 12 (32.9% vs. 39.3%, p = 0.03) and 24 (29.6% vs. 35.7%, p = 0.04)
compared to placebo. The ocrelizumab group also showed significant improvements in brain volume
loss when compared to placebo (0.90% vs. 1.09%, p = 0.02).
Following the approval of ocrelizumab by the FDA in March 2017, Genentech has been required
to undertake a phase IV human clinical trial in young adults to determine whether any side effects
such as increased risk of cancer or effects in pregnant women and their newborns result [49]. However,
in mouse studies it was shown that the drug was present in breast milk, and hence, it is unclear what
effects this may have in newborns, so it is recommended not to be used while breast feeding.
5. Ofatumumab
Ofatumumab is an anti-CD20, human monoclonal IgG1 antibody binding strongly to a
distinct membrane epitope to rituximab and ocrelizumab [41,50]. Ofatumumab is the first type
1 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is fully human, and is currently
licensed for the treatment of Chronic Lymphocytic Leukemia under the brand name Arzerra [50], but it
has also recently been evaluated for use in RRMS. Novartis acquired the rights from GlaxoSmithKline
(GSK) in 2015, to allow for the development of ofatumumab for cancer and autoimmune diseases.
A notable strength of ofatumumab is that it can be administered subcutaneously by patients or
caregivers with an auto-injector pen, which is administered at four-week intervals. In the face of a
chronic disease requiring regular treatment administration, this may provide better access to therapy,
as opposed to typical antibody therapies which necessitate a day to be set aside in a clinic for the
infusion. In August 2020, the FDA approved ofatumumab as a therapy for all forms of relapsing MS,
including CIS, secondary progressive MS and RRMS, in the form of an auto-injector pen. It is expected
to receive approval from the EMA in 2021.
5.1. Pharmacology
Ofatumumab binds to two novel epitopes of the CD20 protein: the small and large extracellular
loops. Once bound by the antibody, the CD20 molecule is not internalized or shed from the cell
surface [24]. As with other anti-CD20 antibodies, after binding target epitopes, ofatumumab causes
antibody-dependent cell lysis to the circulating B cells [51]. The mechanisms of cell lysis are similar to
ocrelizumab, although ofatumumab causes more CDC than ADCC [52].
5.2. Clinical Trials
Ofatumumab has demonstrated strong efficacy in rheumatoid arthritis [53] and hematological
malignancies [54]; however, some studies have also evaluated its role in treating MS (Table 3).
In a small phase 2, double-blind, randomized, placebo-controlled study, 38 patients with RRMS
received either intravenous ofatumumab or a placebo at two-week intervals [55]. A group of 26
patients received fortnightly 100, 300, and 700 mg doses of ofatumumab, while the remaining 12
were placebo-treated. After 24 weeks in two groups, the two treatment arms were swapped, with the
placebo participants receiving ofatumumab. A 99% reduction of new T1 and T2 gadolinium-enhancing
brain lesion activity after 24 weeks of ofatumumab treatment was reported. Moreover, no reduction in
overall serum IgG was observed, and ofatumumab was well tolerated by patients. A second phase 2,
48 week, double-blind, placebo-controlled, randomized and manufacturer-sponsored study named
MIRROR was conducted to examine subcutaneous ofatumumab versus placebo in 231 patients with
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RRMS [56]. The study randomized participants to receive placebo (n = 67), 12 weekly doses of either
3 mg (n = 33), 30 mg (n = 32), or 60 mg (n = 33) of ofatumumab, or finally, 60 mg ofatumumab every
4 weeks (n = 63). A dose of 3 mg ofatumumab was given to the placebo group at week 12 with a second
at 24 weeks during a follow-up phase. The study confirmed that all doses of ofatumumab significantly
decreased new MRI lesions over 12 weeks. Infection-associated AEs were reported in both groups, but
were non-significantly different (25% placebo, vs. 27% ofatumumab at 12 weeks, 29% placebo and 21%
ofatumumab at 24 weeks). An extension of this trial also showed ongoing suppression of new lesions
after 48 weeks with dose-responsive B-cell effects.
Table 3. A Summary of Clinical Trials Using Ofatumumab.
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MS, Multiple Sclerosis; RRMS, Relapsing Remitting Multiple Sclerosis; wk, week; ARR, Annualized Relapse Rate;
GAD, gadolinium.
Two phase 3 randomized, double-blind, active-controlled studies (ASCLEPIOS 1 and ASCLEPIOS
2) have investigated the efficacy of ofatumumab versus teriflunomide in RRMS. The trials reached
their end points, with positive effects reported compared to teriflunomide in relapse rate, confirmed
disease improvement, and number of T1 and T2 gadolinium-enhancing lesions [57]. The safety profile
of ofatumumab was generally good, with similar incidence of AEs in patients receiving it compared to
those who received teriflunomide.
6. Safety
While generally well tolerated, anti-CD20 mAb therapies have some safety considerations that
must be observed. Infusion reactions occur commonly with ocrelizumab therapy, generally within the
initial 24 h following administration due to type 2 hypersensitivity reactions and accompanied cytokine
release [46,58]. Ocrelizumab therapy is contraindicated in active hepatitis B and C patients, so screening
should be considered prior to treatment [11]. The most clinically important adverse events associated
with ocrelizumab are infections secondary to immunosuppression. Post-marketing surveillance
identified that as many as 30% of patients receiving ocrelizumab show hypogammaglobulinemia,
significantly increasing infection risk [59]. The most frequent infections observed in patients treated with
ocrelizumab were nasopharyngitis, upper respiratory tract, herpes zoster exacerbations, and urinary
tract infections [45–47]. Additionally, patients should be examined for vaccination status and refrain
from live vaccines during ocrelizumab treatment. It is worthy of mention that there is a lack of data in
animal or humans on the teratogenicity of ocrelizumab. Exposure to B-cell depleting agents such as
ocrelizumab while pregnant was associated with B-cell depletion in newborns, renal and testicular
toxicity, lymphoid follicle formation in the bone marrow, and death in primate models [43]. As a
result, contraception is recommended for women in the 6 months after the last infusion. There has
also been a tendency to develop neoplasms, specifically different types of breast cancer, presented
more frequently in patients receiving ocrelizumab, but a mechanistic role of the antibody exposure has
not yet been identified [41]. An important safety concern regarding many MS medications is the risk
of progressive multifocal leukoencephalopathy (PML), which has been shown to be attributable to a
number of therapies used in treatment of the disease. Although there were no cases of PML reported
during ocrelizumab treatment in the clinical trials leading to its approval, a small number of cases
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have since been reported in post-market monitoring. Many of these patients have been confounded
by prior treatment with other MS agents such as standard disease modifying therapies (DMTs) and
natalizumab, making a causative link difficult to identify, and the risk/benefit of treatment remains
unchanged [60].
Studies investigating the safety of ofatumumab reported adverse events including infection,
neutropenia, infusion-related reaction, anemia, thrombocytopenia, cough, and pneumonia [61,62].
In the MIRROR study, AEs were reported to be mild to moderate in severity, and no fatal reactions
were reported. Notably, serious AEs were mostly infusion reactions with one case of cytokine-release
syndrome in the hours following the first ofatumumab dose. Other less common AEs occurring
in single patients were cholelithiasis, hypokalemia, angioedema, and urticaria [56]. In two phase 2
trials of RRMS, no cases of opportunistic infection or incident neoplasm were reported and also no
immunogenic responses were observed in any of the patients who received the medication. After FDA
approval for ofatumumab in 2014 for treatment of chronic lymphocytic leukaemia (CLL), it has been
associated with hepatitis B and PML in post-market monitoring. There has been one reported case of a
PML-related death in a patient receiving ofatumumab who had a history of CLL and other comorbid
malignant disease [63].
While the anti-CD20 therapies appear to have strong efficacy and favorable safety profiles, there is
some concern regarding adverse events when transferring to, or from, another therapeutic such as
teriflunomide or interferon beta. Due to the relative infancy of these therapeutics in the treatment of
MS, the risk profile of changing to, or from, these medications is currently unknown [64]. However,
in head-to-head comparisons of other therapies and the anti-CD20 agents, generally, the efficacy and
safety of the agents teriflunomide, interferon beta, or fingolimod, is typically lower, making switching
of medications likely to be of benefit overall [64]. Until the antio-CD20 agents have been in widespread
use, close monitoring of patients in the months after medication switching is recommended to identify
any adverse events.
In conclusion, the most common adverse events reported with anti-CD20 monoclonal antibodies
are infusion reactions, which are believed to be due to excessive CDC [65]. When these agents are
intravenously administrated, it is essential to have established safety protocols such as premedication
with an antihistamine, such as diphenhydramine, and antipyretics such as acetaminophen. To reduce
the risk of serious AEs, preventative dosing with glucocorticoids may also be considered.
7. Conclusions
Anti-CD20 antibody-mediated, B-cell depleting therapies established a new and promising avenue
in the treatment of RRMS and PPMS. They have yet to be evaluated in other forms of MS, such as
SPMS, and so their use cannot be supported in this. They are perceived as a promising alternative or
complement to the current panel of DMTs. The recorded data delivered worldwide from clinical trials
confirms the benefits of these agents on both clinical and imaging assessment of inflammatory activity
for patients with RRMS, as well as also confirming benefits in patients with PPMS in reducing disability
accumulation [66]. Three major anti-CD20 mAbs have been tested in MS; rituximab, ocrelizumab,
and ofatumumab. Broadly, in clinical trials they have been shown to reduce time to disease progression
and radiographic findings. Despite these results, there is still further research required to fully evaluate
the full risk–benefit ratio of anti-CD20 therapies, as well as to evaluate their impact with extended
periods of use, particularly when compared to more established traditional therapies. Further analysis
to understand the mechanisms by which B-cell depletion is so effective in MS will also advance the
understanding of pathogenesis in MS, as well as identify further strategies for therapeutic approaches.
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